SCHEMBL5406604

SCHEMBL5406604

COc1ccc2c(c1)CCN2S(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]c(C)c(C(=O)O)c1C)C(=O)N2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.66
ALK Q9UM73 1/20 0.53
AURKB Q96GD4 9/20 0.52
FLT3 P36888 6/20 0.52
KDR P35968 7/20 0.51
KIT P10721 1/20 0.51
FLT4 P35916 1/20 0.51
AURKA O14965 5/20 0.50
PDGFRB P09619 4/20 0.50
LRRK2 Q5S007 1/20 0.50
AURKC Q9UQB9 1/20 0.50
FGFR1 P11362 4/20 0.47
EGFR P00533 1/20 0.47
MEN1 O00255 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 1/20 0.46
PTK2B Q14289 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413334 0.91 MET (0.82) METALKAURKBFLT3KDR
SCHEMBL5405518 0.90 MET (0.67) METALKAURKBFLT3KDR
SCHEMBL5403331 0.90 MET (0.67) METALKAURKBFLT3KDR
SCHEMBL5405465 0.89 MET (0.82) METALKAURKBFLT3KDR
SCHEMBL14595083 0.86 KDR (0.72) METALKAURKBFLT3KDR
SCHEMBL5413896 0.85 MET (0.75) METALKAURKBFLT3KDR
SCHEMBL3267645 0.82 ALK (0.73) METALKAURKBFLT3KDR
SCHEMBL5407095 0.81 MET (0.59) METAURKBKDRAURKAPDGFRB
SCHEMBL5406649 0.81 MET (0.83) METALKAURKBFLT3KDR
SCHEMBL5406612 0.81 MET (0.83) METALKAURKBFLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US claimed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US claimed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 MET 2590/4885ALK 612/4885AURKB 414/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM MET 2434/4885ALK 1165/4885AURKB 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.